igor-vkv-shutterstock-com-russia-
Igor Vkv / Shutterstock.com
15 December 2016Big PharmaNatalia Gulyaeva and Maria Sedykh

Pharma collaboration in Russia: the dos and don’ts

The life sciences industry has remained dynamic even in the years of economic downturn. Clearly, this high IQ industry is smart enough to adjust to the changing market conditions and to see the silver lining.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
4 February 2021   Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug remdesivir without the authorisation of the drug’s patent owner, Gilead Sciences.

More on this story

Big Pharma
4 February 2021   Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug remdesivir without the authorisation of the drug’s patent owner, Gilead Sciences.

More on this story

Big Pharma
4 February 2021   Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug remdesivir without the authorisation of the drug’s patent owner, Gilead Sciences.